These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 4252802)

  • 1. [Fibrinolysis activities and factor XIII in the neonatal period. 1. Fibrinolysis activity and fibrin degradation products in the neonatal period].
    Yamada Z
    Nihon Shonika Gakkai Zasshi; 1971 Apr; 75(4):294-6. PubMed ID: 4252802
    [No Abstract]   [Full Text] [Related]  

  • 2. Fibrinogen-fibrin degradation products during labour and during the puerperium.
    Hahn L
    Acta Obstet Gynecol Scand Suppl; 1974; 28():1-6. PubMed ID: 4525174
    [No Abstract]   [Full Text] [Related]  

  • 3. Fibrinogen/fibrin degradation products (FDP/fdp). Characterization, anticoagulant activity, and influence on laboratory assays.
    Arnesen H
    J Oslo City Hosp; 1977 Jun; 27(6):69-80. PubMed ID: 142131
    [No Abstract]   [Full Text] [Related]  

  • 4. A review of the basic mechanisms of fibrinogen to fibrin conversion and of fibrinolysis: intravascular coagulation versus primary fibrinolysis.
    Colick JA; Fisher LM
    Va Med Mon (1918); 1970 May; 97(5):310-4 passimass. PubMed ID: 4276992
    [No Abstract]   [Full Text] [Related]  

  • 5. [Fibrinolysis activities and factor XIII in the neonatal period. 2. Relationship between factor XIII and fibrinolysis activities].
    Yamada Z
    Nihon Shonika Gakkai Zasshi; 1971 Apr; 75(4):297-303. PubMed ID: 4252803
    [No Abstract]   [Full Text] [Related]  

  • 6. A fibrinogen concentrate Haemocomplettan (Riastap) or a Factor XIII concentrate Fibrogammin combined with a mini dose of tranexamic acid can reverse the fibrin instability to fibrinolysis induced by thrombin- or FXa-inhibitor.
    He S; Johnsson H; Zabczyk M; Hultenby K; Cao H; Blombäck M
    Br J Haematol; 2013 Mar; 160(6):806-16. PubMed ID: 23360261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Fibrinolysis].
    Levy G; Michault A; Jamet M
    Ann Anesthesiol Fr; 1978; 19(8):703-8. PubMed ID: 31114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Fibrinogen and its break-down products].
    Gormsen J; Feddersen C
    Ugeskr Laeger; 1973 Aug; 135(32):1678-82. PubMed ID: 4272617
    [No Abstract]   [Full Text] [Related]  

  • 9. [Diagnostic significance of proteolytic breakdown products of fibrinogen and fibrin].
    Heene DL; Genth K
    Internist (Berl); 1984 Feb; 25(2):93-101. PubMed ID: 6231262
    [No Abstract]   [Full Text] [Related]  

  • 10. Fibrinogen-fibrin degradation products in uterine and peripheral blood during Caesarean section.
    Hahn L
    Acta Obstet Gynecol Scand Suppl; 1974; 28():1-7. PubMed ID: 4599651
    [No Abstract]   [Full Text] [Related]  

  • 11. [Nonenzymatic fibrinolysis].
    Dzhurdzhev A; Atanasov K
    Vutr Boles; 1981; 20(3):18-22. PubMed ID: 6455858
    [No Abstract]   [Full Text] [Related]  

  • 12. [A new quick and sensitive method for analysis of fibrin metabolism products in serum--theoretic and practical meaning].
    Gormsen J
    Nord Med; 1970 Jul; 84(31):999. PubMed ID: 4247659
    [No Abstract]   [Full Text] [Related]  

  • 13. [Kinetics of fibrin lysis by plasmin: inhibition by fibrin degradation products].
    Zhitkova IuV; Aĭsina RB; Varfolomeev SD
    Bioorg Khim; 1996 Dec; 22(12):911-5. PubMed ID: 9054342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Fibrinolysis phenomenon (author's transl)].
    Fujimaki M; Suzuki H; Yasui T; Yatabe M; Ikematsu S
    Rinsho Byori; 1974 Aug; 22(Suppl):234-41. PubMed ID: 4610225
    [No Abstract]   [Full Text] [Related]  

  • 15. [The role of DL and DH degradation products in the reactions of the plasmin hydrolysis of fibrinogen and fibrin].
    Rozenfel'd MA; Leonova VB; Khavkina LS
    Izv Akad Nauk SSSR Biol; 1991; (3):334-42. PubMed ID: 1835465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparative study of four methods for detecting fibrinogen degradation products in patients with various diseases.
    Thomas DP; Niewiarowski S; Myers AR; Bloch KJ; Colman RW
    N Engl J Med; 1970 Sep; 283(13):663-8. PubMed ID: 4247823
    [No Abstract]   [Full Text] [Related]  

  • 17. Studies on the proteolysis of fibrinogen and fibrin by Aspergillus ochraceus enzyme as compared to the action of plasmin.
    Teisseyre E; Latallo ZS; Kopeć M
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1974; 101(1):99-110. PubMed ID: 4134484
    [No Abstract]   [Full Text] [Related]  

  • 18. Fibrinogen-fibrin degradation products and factor XIII.
    Miloszewski K; Sheltawy MJ; Losowsky MS
    Acta Haematol; 1974; 51(6):321-30. PubMed ID: 4212013
    [No Abstract]   [Full Text] [Related]  

  • 19. Fibrin degradation in the synovial fluid of rheumatoid arthritis patients: a model for extravascular fibrinolysis.
    Carmassi F; de Negri F; Morale M; Song KY; Chung SI
    Semin Thromb Hemost; 1996; 22(6):489-96. PubMed ID: 9122713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Assay methods and significance of fibrin-fibrinogen degradation products in blood].
    Shinada S
    Nihon Ketsueki Gakkai Zasshi; 1972 Oct; 35(5):607-16. PubMed ID: 4677376
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.